The New York Blood Center Enterprises (NYBCe) Clinical Apheresis Service is now offering Lipoprotein Apheresis (LP-APHE) as part of its mobile apheresis services. LP-APHE will be performed using the Liposorber® MA-03 System (Kaneka Pharma America). LP-APHE is a type of selective apheresis by which atherogenic lipoproteins (such as LDL and Lp(a)) are efficiently removed while most other proteins (including the atheroprotective HDL) are not. This is in contrast to therapeutic plasma exchange (TPE) where all plasma proteins are lost with the removed plasma, and a replacement fluid is required.

Conditions treated with LP-APHE include hyperlipoproteinemias such as Familial Hypercholesterolemia (FH), elevated Lp(a), and other high risk lipoproteinemias where patients have experienced cardio-vascular and/or cerebrovascular events. It is also used to treat certain sub-populations of patients with focal segmental glomerulosclerosis (FSGS).

REFERENCES


Heigl, F., R. Hettich, et al. (2015). “Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.” Atherosclerosis Supplements 18(0): 154-162.


FOR MORE INFORMATION ON LP-APHE THERAPY, CONTACT NYBC CLINICAL SERVICES AT 914.784.4602